- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about VXRT
Recent news which mentions VXRT
From Motley Fool
These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge
February 23, 2022
From Motley Fool
This Reopening Stock Has A Better 1-Year Return Than Moderna, Pfizer, BioNTech, Novavax And Vaxart
February 17, 2022
From Benzinga
4 Under-the-Radar Stocks With 319% to 645% Upside in 2022, According to Wall Street
January 29, 2022
From Motley Fool
Could Vaxart's Vaccine Pill Help to End the Pandemic?
January 27, 2022
From Motley Fool
4 of the Fastest-Growing Stocks on the Planet in 2022
January 27, 2022
From Motley Fool
Which Vaccine Stocks Will Make You a Fortune in 2022?
January 12, 2022
From Motley Fool
Is This Vaccine Stock a Buy?
January 10, 2022
From Motley Fool
Vaxart: Oral Covid-19 Vaccine Is Interesting, But Questions Linger
January 10, 2022
From InvestorPlace
Where to Invest $100,000 in 2022
January 02, 2022
From Motley Fool
Tickers
VXRT
From InvestorPlace
2 Top Healthcare Stocks Ready for a Bull Run in 2022
December 20, 2021
From Motley Fool
3 Growth Stocks With More Potential Than Any Cryptocurrency
December 15, 2021
From Motley Fool
From Motley Fool
Why Shares of Pfizer, Ocugen, and Vaxart Are Losing Ground Today
December 06, 2021
From Motley Fool
From InvestorPlace
Cramer Gives His Opinion On Nokia, Delta Air Lines And More
December 01, 2021
From Benzinga
3 Vaccine Latecomers That Could Double Your Money
November 21, 2021
From Motley Fool
3 COVID Pill Stocks That Might Be Game-Changers
November 05, 2021
From Motley Fool
5 Biotech Stocks With 105% to 386% Upside, According to Wall Street
November 03, 2021
From Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2021
November 02, 2021
From Benzinga
Novavax is Now a Riskier Play, but Still One to Keep Your Eye On
October 25, 2021
From InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.